N-[2-[2-[[(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenyl]amino]ethoxy]ethyl]pyridine-3-carboxamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: N-[2-[2-[[(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenyl]amino]ethoxy]ethyl]pyridine-3-carboxamide
• 化学式: C₃₂H₄₇N₃O₂
• 分子量: 505.7
• InChiKey: KSSJNRNBXIVDKJ-KUBAVDMBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.8
• 重原子数：
  37
• 可旋转键数：
  22
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  63.2
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• METHODS OF LOWERING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9)
  申请人：Catabasis Pharmaceuticals, Inc.

  公开号：EP2854787A2

  公开（公告）日：2015-04-08
• USE OF FATTY ACID NIACIN CONJUGATES FOR TREATING DISEASES
  申请人：Catabasis Pharmaceuticals, Inc.

  公开号：EP2941252A2

  公开（公告）日：2015-11-11
• [EN] METHODS OF LOWERING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9)<br/>[FR] MÉTHODES DE DIMINUTION DE LA PROPROTÉINE CONVERTASE SUBTILISINE/KEXINE DE TYPE 9 (PCSK9)
  申请人：CATABASIS PHARMACEUTICALS INC

  公开号：WO2013177536A2

  公开（公告）日：2013-11-28

  The invention relates to new methods of modulating cholesterol by inhibiting proprotein convertase subtilisin/kexin type 9 (PCSK9) with fatty acid derivatives; and new methods for treating or preventing a metabolic disease comprising the administration of an effective amount of a fatty acid derivative. The present invention is also directed to fatty acid bioative derivatives and their use in the treatment of metabolic diseases.
• [EN] USE OF FATTY ACID NIACIN CONJUGATES FOR TREATING DISEASES<br/>[FR] UTILISATION DE CONJUGUÉS D'ACIDES GRAS ET DE NIACINE EN VUE DU TRAITEMENT DE MALADIES
  申请人：CATABASIS PHARMACEUTICALS INC

  公开号：WO2014107730A2

  公开（公告）日：2014-07-10

  The invention relates to fatty acid niacin conjugates; compositions comprising an effective amount of a fatty acid niacin conjugate; methods for treating or preventing an metabolic disease comprising the administration of an effective amount of a fatty acid niacin conjugate, and methods for treating or preventing an metabolic disease comprising the administration of an effective amount of a fatty acid niacin conjugate and another therapeutic agent.